31 Women with hyperprolactinemia (HP) and 30 women with normal lu teinizing phase of cycles were investigated in this study. The patients were divided into pituitary adenoma group(Ⅰ) and functional HP group(Ⅱ) by CT and MRI examinations. Each group above was subdivided into hypoestrogenic(hypoestrogenic Ⅰ, hypoestrogenic Ⅱ) and euroestrogenic (euroestrogenic Ⅰ, euroestrogenic Ⅱ) groups by means of estrogen levels and cervical mucus. Basic hormone levels of all groups were measured by radioimmunoassy(RIA). The results showed that the prolactin levels were higher and LH, FSH, E_2 T and P levels lower in women with HP than in control women. The prolactin levels of Ⅰ exceeded these of Ⅱ markedly. LH, FSH, E_2, T and P were similar in both Ⅰ and Ⅱ. LH and FSH were similar in both hypoestrogenic and euroestrogenic groups except E_2. In summary, this study indicates that (1) The patients may present hypogonadotropic and hypogonadal functions; (2) Gonadotropic and gonadal functions of Ⅰ are similar to those of Ⅱ; (3) There is probably size heterogeneity of prolactin in pituitary adenoma and functional HP.

The change of T cell subsets of peripheralblood were tested in 12 patients with prematureovarian failure (POF), among them 10 patients superoxide dismutase (SOD) activity in erythrocytewas also tested. The results showed that the num-ber of T_3, T_4 cells T_4/T_8 ratio and SOD activitywas significantly lower in patients with POF thanin normal controls, which indicated that the func-tion of proliferation and differentiation of T lym-phocyte was inhibited, the immunoregulation wasinbalanced and the ability of resistance to lipid per-oxidation was lower in patients with POF. There-fore, the results suggests that T cell subsets andSOD activity testing in patients with POF have val-ue in the investigation of the cause of the deseaseas well as in the diagnose and treatment.

Most of the luteinized unruptured follicle syndrome(LUFS)happens to women with menstrual disorders and is one of the important factors in "unexplained infertility". The mechanism of LUFS is still unknown. Using classic criteria, such as basal body temperature, serum progesterone, endomtrium biopsy and crystals of cervical mucous one can not distinguish the LUFS cycles from the ovulatory ones. There were low reports in our country in this aspect. In the reproductive endocrinology and infertility outpatient department we have found 2 cases of LUFS through ultrasound and laboratory findings. In this article, the pathophysiologic mechanism of this sydrome, its diagnostic method and index are discussed, and some problems concerning fertility and sterility are proposed.

Objective To evaluate the impacts of rosiglitazone and metformin on ovarian response, hirsutism and insulin action in women with polycystic ovary syndrome (PCOS). Methods Ninety women resistant to clomiphene citrate with PCOS were randomized, 40 cases to rosiglitazone group, 50 cases to meformin group. Rosiglitazone and metformon were administered for 6 months in combination with clomiphene citrate on cycle day 5th to 9th, respectively. The clinical evaluations were performed monthly. Reproductive hormone, serum glucose and insulin levels were observed before and after treatment. The data were analyzed using repeated analysis of variance (ANOVA). Results There were significant changes in reducing hirsutism score, serum testosterone level, LH/FSH ratio, and restoration of ovarian ovulation after metformin or rosiglitazone administration respectively (P<0.05). Insulin sensitivity was more significantly improved in the rosiglitazone group than in metformin group (P<0.05) After treatment. Homa IR and Homa β were decreased from 1.54±0.34 to 0.83±0.38 and from 5.83±0.55 to 4.95±0.54 (P<0.05) in the rosiglitazone group. The body mass index(BMI) was decreased from 25.30±3.64 to 23.83±2.32 in the metformon group (P<0.05). There were no significant changes in ovulation rate and pregnancy rate between groups (P>0.05). Conclusion Rosiglitazone can increase insulin sensitivity. Metformon may reduce BMI. They all restore regular menstrual cycles, increase pregnancy rate, and reduce testosterone and LH concentration in women with polycystic ovary syndrome.